Furosemide treats fluid retention and sometimes hypertension. Confidence: high; comparative benefit uncleared. Overview.
- Monitoring covers blood pressure, kidney function and electrolytes.
- Fluid and potassium plans require individual advice.
- Extra tablets or liquid: urgent advice, before symptoms.
- Confirm formulation and country-specific feeding restrictions.
- The dated Lasix notice cannot establish stock.
Table of contents
- Evidence summary
- Product identity
- How it works
- Treatment context
- Fluids and supplements
- Human studies
- Urgent effects
- Interactions
- Restrictions
- Use and monitoring
- Evidence boundaries
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Licensed roles | UK/US labels. | Maker sources, 4/D. | Safety context; efficacy uncleared. |
| Monitoring | SPS framework. | NHS commissioned route; contributor/trial chains unclosed. | Individual checks; no home cutoffs. |
| Comparative/postpartum trials | TRANSFORM-HF and FoR BP. | NHLBI; author interests or unresolved supply. | Methods reviewed; no cleared benefit estimates. |
| Supplements | Dated NCCIH safety account. | Public/gift route; credited-reviewer interests unresolved. | Disclosure and compatibility review, not replacement efficacy. |
| Prescribing use | England PCA. | Agency public/service finance; allocation unclosed. | Items, not patients or worldwide popularity. |
Product identity
The examined Ipca UK tablets contain furosemide; check the supplied pack. Tablet leaflet.
Frusol is Rosemontβs UK furosemide liquid. Ethanol, maltitol and propylene glycol require pack checks; newborn or tube-administration questions need specialist advice. Liquid leaflet.
On August 14, 2026, FDA determined the discontinued US Lasix tablets were not withdrawn for safety or effectiveness. This permits the regulatory reference to remain; it does not establish stock, availability elsewhere or suitability for an individual. Official determination.
England recorded 11,312,344 furosemide prescription items in FY2025/26, chemical code 0202020L0. Original workbook.
PCA covers community dispensing, including hospital-issued prescriptions dispensed there, and excludes hospital dispensary supplies. Items are not unique people, diagnoses or evidence that a medicine is best. Dataset definitions.
Scope: oral single-ingredient treatment. See the swollen-ankle assessment guide for broader diagnosis.
How it works
Furosemide increases renal salt/water removal. It controls fluid retention and blood pressure without curing the underlying condition. Mechanism.
An independent comparison asks which outcome was measured, how participants were selected, whether allocation and follow-up were reliable, and who financed the work. A mechanism, symptom change and longer-term patient outcome require separate evaluation. This review assigns no independent benefit estimate from a mechanism statement.
Treatment context
Heart-failure care is long term and depends on its type, severity and other conditions. Diuretics sit alongside other medicines and, for selected people, devices, surgery and rehabilitation; furosemide does not replace the whole care plan. Heart-failure context.
In heart failure, new breathlessness during ordinary activity or lying down, frothy pink phlegm or sudden weight gain need an urgent GP appointment or NHS111. Severe breathing difficulty or unresponsive collapse needs 999. These disease warnings require assessment rather than an extra self-selected diuretic dose. Disease urgency.
US roles: cardiac/cirrhotic/renal oedema, adult hypertension. Cirrhotic ascites: close observation, preferably hospital initiation; fluid/electrolyte shifts can precipitate hepatic coma. US label.
The Ipca leaflet lists cirrhosis as a do-not-take condition. UK leaflet.
Its professional record restricts liver-related pre-coma/coma. Professional record.
Ask the prescriber to resolve the product discrepancy; do not self-adjust treatment.
Questions for the visit: which product document governs the prescription, and how does it fit the wider disease plan? See the heart-failure guide.
Fluids and supplements
Ask the doctor about fluid intake; requirements vary. Alcohol can worsen dizziness/dehydration. Fluid advice.
Liquorice and potassium products need review; ask before changing supplements or prescribed replacements. Liquid interactions.
NCCIH warns that supplements can interact with medicines and that many have not been tested in pregnancy, breastfeeding or children. Tell the care team what you use; a natural label does not establish compatibility. Dated safety account.
No independent evidence reviewed here establishes a herbal water pill as a replacement for prescribed treatment. A supplement comparison would need its own specified product, human endpoints and funding audit. This article therefore supplies no supplement brand ranking or potassium regimen.
Human studies
TRANSFORM-HF randomised 2,859 US patients after a heart-failure admission to torsemide or furosemide. It was open label, covered different ejection fractions and left dosing to clinicians. Switching, discontinuation and missing follow-up limit interpretation; this is not a home conversion study. Original methods.
The comparative trial excluded dialysis and people with a history of transplant or ventricular-assist-device implantation. Its open treatment allocation and clinician-selected doses matter when interpreting a comparison of strategies. A result in this hospital-discharge setting cannot determine a conversion rule for every stable outpatient, or answer whether a particular liquid and tablet pack are interchangeable. Population and design.
FoR BP randomised 384 women with gestational hypertension or pre-eclampsia in a short, masked placebo-controlled postpartum study. It excluded selected cardiac, renal and other high-risk conditions. Readmission outcomes were underpowered, and breastfeeding difficulty was self-reported rather than infant drug-level or long-term safety assessment. Original methods and limits.
The postpartum trial was conducted at one centre with a text-based home blood-pressure programme and clinician treatment algorithm. Its primary questions concerned persistent hypertension and time to blood-pressure resolution. That supported-care setting and selected population limit extrapolation to unsupervised postpartum use or serious long-term maternal outcomes. Setting and endpoints.
Randomisation improves comparability but cannot resolve a financierβs influence. Evidence also needs reliable follow-up and an audit of authors, supplied products and endpoints. These studies remain methods/context sources here; the article supplies no independent superiority, postpartum benefit estimate or regimen.
Urgent effects
Call 999 in the UK, or local emergency services elsewhere, for throat/tongue swelling, severe breathing or swallowing difficulty, collapse or other suspected anaphylaxis. Emergency priority overrides routine medicine-continuity advice. Emergency recognition.
UK NHS111 now (local urgent care elsewhere): blistering mouth/eyes/nose/genitals with flu-like illness; flank pain, fever or bloody/difficult urine; marked dehydration, reduced/dark urine, dizziness or confusion. NHS urgency.
Ringing ears/hearing loss, jaundice, fever, weakness/cramps, rapid heartbeat or reduced urine: call the doctor immediately or seek emergency assessment. Causation remains uncertain. AHFS urgency.
Blood-cell disorders (blood dyscrasias): immediate stopping and urgent clinical assessment. UK warning.
Effects include increased urination, thirst, dizziness, headache, twitches. Avoid driving/machinery while dizzy/drowsy. NHS effects.
Interactions
Lithium, NSAIDs, digoxin/antiarrhythmics, ACE inhibitors/ARBs and certain antibiotics pose toxicity, rhythm, pressure, kidney or hearing risks. UK interactions.
The US label prohibits ethacrynic-acid combination and discourages chloral-hydrate co-use. US interactions.
Check every prescription, painkiller, vitamin and herb with the pharmacist. AHFS flags salicylates/NSAIDs and sucralfate; administration plans require professional advice. AHFS checks.
Do not self-adjust prescriptions from this abbreviated list.
Restrictions
Ipca restrictions: no urine; selected renal/poisoning states; salt/volume depletion, dehydration/low pressure; potassium products/sparing drugs; Addisonβs; digitalis poisoning; liver pre-coma/coma. Requires product-specific assessment. UK restrictions.
US: no urine/allergy contraindicated. Severe kidney deterioration with reduced urine requires clinician-directed discontinuation; urinary obstruction, diabetes/gout and permanent hearing-damage warnings apply. Warnings.
UK pregnancy: compelling medical reasons and fetal-growth monitoring. Breastfeeding is prohibited. UK reproduction.
US nursing: caution, milk transfer, possible lactation suppression. US nursing.
Pregnancy/feeding: ask the prescriber before relying on routine continuation.
Use and monitoring
Too many Ipca tablets: doctor or nearest hospital immediately, without waiting for symptoms. No double missed dose; discuss routine stopping. Tablet instructions.
Too much Frusol: doctor or hospital straight away; bring the pack. Verify strength/deviceβequal volumes may differ. Liquid instructions.
More than prescribed: NHS111 immediately. Vomiting/diarrhoea/fever: pharmacist/doctor advice or their existing plan, without a home hold/restart rule. NHS taking.
SPS describes blood-pressure, electrolyte and kidney-function checks before treatment and after changes, with follow-up tailored to risk. Older age, kidney disease, diabetes, peripheral arterial disease and interacting combinations can require closer review. Professional monitoring.
SPS separates routine surveillance from professional responses to altered kidney function or electrolytes. A clinician must interpret a result alongside volume status, interacting medicines and symptoms. The frameworkβs dates and bibliography are visible below; no laboratory category here is converted into a home dose change or a universal follow-up interval. Interpreting monitoring.
Monitoring questions: who reviews results, adjusts treatment and responds to illness or a missed review?
Evidence boundaries
US animal findings cannot establish human efficacy, infant safety or personal overdose thresholds. Animal boundary.
Yellow Card accepts suspected medicine problems. Reporting is useful but cannot establish causation or an adverse-effect frequency by itself; urgent care takes priority over completing a report. Reporting service.
A labelβs precautions and an independently cleared benefit comparison serve different purposes. Commercial product records are used for their specific licensed instructions and safety boundaries, with the sellerβs interest visible below. No source is promoted to independent efficacy evidence because a government library hosts it.
Funding and source roles
Research funding at a glance
49 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this articleβs source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS furosemide | DHSC route below; contributor/page/trial payments unclosed. | UK national website. | Tier 2; public clinical context | B provisional. July 7, 2026. Education; efficacy uncleared. |
| Ipca SmPC | Ipca UK holder; parent/eMC routes below. | UK; Sunderland. | Tier 4; maker source | D. May 26, 2025; licence/safety only. |
| Ipca leaflet | Same holder and publisher routes below; supplied-pack plant unverified. | United Kingdom. | Tier 4; maker source | D. May 2025. Patient warnings, not comparative benefit. |
| Frusol leaflet | Rosemont holder/manufacturer; seller/capital routes below. Paid eMC host. | United Kingdom; Leeds. | Tier 4; maker source | D. February 2024. Exact current pack/stock unverified. |
| Hikma label | Hikma Pharmaceuticals USA Inc. distributor; seller/NLM below. | US; New Jersey. | Tier 4; maker source | D. November 2025; February 2026 listing; efficacy uncleared. |
| SPS furosemide monitoring | Commissioned NHS route below; contributor/bibliography finances unclosed. | United Kingdom NHS service. | Tier 2; professional context | B provisional. February 20, 2025; individual framework, not home thresholds. |
| AHFS furosemide | ASHP content; publishing/sponsor routes and separate NLM host below. | United States; Bethesda. | Tier 3; mixed institutional route | C provisional. April 15, 2025. Author/underlying-study interests unclosed. |
| NHS heart failure | Shared national website route below; exact contributor/trial interests unclosed. | United Kingdom. | Tier 2; public clinical context | B provisional. June 26, 2026; care overview, no individual selection. |
| NHS anaphylaxis | Shared national website route below; exact author interests unclosed. | United Kingdom. | Tier 2; emergency context | C provisional. June 2023; review overdue June 2026. |
| NCCIH supplement safety | Congressional/gift routes below; Hopp/Shurtleff credited, individual/page interests unclosed. | United States NIH; Bethesda. | Tier 3; credited-source context | C provisional. January 2019; Hopp historical industry/patent work separately traced. No efficacy clearance. |
| Hopp official biography | Past Shaman Pharmaceuticals patent work, Phyto-Technologies herbal R&D and AMRI employment stated. Current royalties/receipts unclosed. | United States; NCCIH, Bethesda. | Tier 3; own career record | B provisional. Undated biography; historical work is not 2019 page payment. |
| Shurtleff official biography | Federal NIH career stated; full individual interests and safety-page payments unclosed. | United States; NCCIH, Bethesda. | Tier 3; own career record | B provisional. Undated biography; job role is not a complete financial declaration. |
| TRANSFORM-HF original, 2023 | NHLBI grants. Anstrom: Merck/Bayer grants during conduct. Other authors: commercial fees/support; Testani royalties/patents. Merck route; Bayer route. Historical contracting entities/award allocations, other counterparties and publisher chains unclosed. | United States trial. | Tier 4; author commercial grants during conduct | D. Conservative financial screen, not claimed protocol sponsorship or distorted results; comparative efficacy excluded. |
| FoR BP original, 2021 | NHLBI grant. Published no-conflict statement; Penn packaged drug/placebo, exact manufacturer/supply chain unclosed. | United States; Philadelphia. | Tier 2; unresolved financial chain | B provisional. Published declaration is not every historical receipt; no cleared benefit estimate. |
| Merck & Co/MSD 2025 results | Medicine/vaccine/animal-health sales; alliance/manufacturing revenue and investment income. Identity. Exact historical disclosed Merck contracting entity, investigator payments and beneficial investors unclosed. | United States; Rahway, New Jersey. | Tier 4; seller financial statement | D. February 3, 2026; own results and unaudited schedules, not full audited annual accounts or clinical efficacy. |
| Merck & Co/MSD investor resources | NYSE MRK public company; MSD name outside US/Canada. Exact historical Anstrom contracting entity and complete ultimate investors unclosed. | United States headquarters: 126 East Lincoln Avenue, Rahway, New Jersey. | Tier 4; seller identity | D. Undated own contact/shareholder body; current identity does not identify an earlier grant recipient/payment. |
| Bayer annual report 2025 | Pharmaceutical, consumer-health and crop-science sales; licences/royalties, other operating/financial income, public equity and debt. Exact historical Anstrom award and full beneficial investors unclosed. | Germany headquarters; Leverkusen. | Tier 4; seller finance | D. March 2026; actual 430-page report, selected corporate/income/debt notes, not clinical efficacy or historical payment proof. |
| Ipca annual report 2025/26 | Medicine/API sales, services, export incentives and other income. UK subsidiary 100%. Kaygee Investments 25.49%; complete beneficial investors/page receipts unclosed. | India; registered Mumbai. | Tier 4; seller finance | D. Actual 272-page original, selected ownership/revenue notes; not investigator-payment proof. |
| Hikma financial statements 2025 | Generic/branded/injectable sales and services; US subsidiary 100% in note 38. Exact product revenue/pack plant/payments unclosed. | UK parent; US subsidiary, Berkeley Heights, New Jersey. | Tier 4; seller finance | D. Actual 33-page financial section, selected revenue/subsidiary notes. |
| Hikma governance report 2025 | Public shareholders; Darhold 27.04% voting rights at December 31, 2025. Director/family-trust interests stated; complete beneficial investors unclosed. | United Kingdom listed company. | Tier 4; seller control report | D. Actual 30-page section; dated ownership, not current individual trial payments. |
| Hikma own contact | Commercial group; exact financial allocations in separate report. Address is not a factory claim. | Global headquarters: 10 Portman Square, London, UK. US headquarters: Berkeley Heights, New Jersey. | Tier 4; seller identity | D. Undated current contact body; no supplied-pack manufacturing inference. |
| Rosemont December 2025 statement | Liquid-medicine manufacture/distribution; own statement calls Inflexion ultimate parent. Complete audited revenue/current beneficial investors unclosed. | United Kingdom; Rosemont House, Braithwaite Street, Leeds. | Tier 4; seller business record | D. Actual four-page statement; ownership claim separately checked against filed control/capital. |
| Rosemont filed control | Primrose Midco 1 Ltd declared at least 75% shares/votes and director rights; notified November 2025. Exact ultimate investors unclosed. | United Kingdom; England/Wales controller. | Tier 3; company-filed record | B provisional. Companies House does not verify accuracy; no page-payment proof. |
| Rosemont filing history | 2025 accounts filed March 27, 2026; linked full accounts retrieval failed. No audited amounts adopted. | United Kingdom; England/Wales company. | Tier 3; company-filed record | B provisional. Filing existence differs from reading full financial statements. |
| Inflexion continuation fund announcement | Β£2.3 billion multi-asset fund; Rosemont included. Lead underwriters Carlyle AlpInvest, HarbourVest and Lexington. Full beneficial LPs/product allocation unclosed. Manager office. | UK manager; international capital. | Tier 4; investor statement | D. Dated 2025 announcement; approvals condition stated, later portfolio corroborates reinvestment. |
| Inflexion portfolio, October 2025 | Continuation Fund I reinvested in Rosemont in May 2025. Exact asset allocation and complete beneficial fund investors unclosed. | United Kingdom manager; UK medicine company. | Tier 4; investor record | D. Actual six-page dated portfolio; not a 2026 full capital ledger. |
| Inflexion own locations | Private-equity manager; full current fund revenues and investors not reported here. | United Kingdom office: 47 Queen Anne Street, London. | Tier 4; investor identity | D. Actual contact body; office location, not every underwriter jurisdiction. |
| Rubicon own venture record | States Validus acquisition February 14, 2024; separate dated report traces 100% via AdvaGen. Current exact capital/receipts unclosed. | Parent corporate office Thane, India; acquired US business. | Tier 4; seller transaction | D. Own group statement, not complete current beneficial ownership. |
| Rubicon annual report 2024/25 | Goods/research services, export benefits/royalties and other income. 100% Validus via AdvaGen Holding acquisition recorded. FY2026 full report not retrieved. | India parent; United States subsidiary. | Tier 4; seller finance | D. Actual 152-page dated original, selected financial/acquisition notes. Full current investors/page payments unclosed. |
| ASHP treasurer report, 2025 | FY2024 audit; meetings/exhibits, publishing, accreditation/consulting and investment income. FY2025 forecast/FY2026 budget are not actual results. | United States; Bethesda. | Tier 3; institutional fiscal report | B provisional. Actual 60-page packet, selected treasurer pages; page allocation and current full accounts unclosed. |
| ASHP corporate/advertising routes | Advertising, sponsorships, publishing partnerships and institutional sales offered. Exact AHFS-page receipts unclosed. | United States; 4500 East-West Highway, Bethesda. | Tier 3; own business disclosure | C provisional. Institutional marketing route, not a named furosemide-page sponsor. |
| ASHP historical corporate support | Amgen, Baxter, BD, BMS, Merck, Novartis, Pfizer and others listed for June 2019βMay 2020. No current page payment inferred. | United States association; international companies. | Tier 3; own sponsor disclosure | C provisional. Dated educational support; not the 2026 donor ledger. |
| FDA Lasix determination, August 2026 | Regulator finance. Validus NDA holder; company group separately traced. Exact application/author payments unclosed. | United States FDA. | Tier 3; regulatory context | B provisional. Official document 2026-16648; status, not independent comparative efficacy. |
| FDA FY2026 operating plan | Public budget authority plus regulated-industry fees, including generic/prescription drug programmes. Exact application allocation unclosed. | United States FDA/HHS; Silver Spring, Maryland. | Tier 3; regulator fiscal report | B provisional. Actual five-page plan; public accountability and fee/policy incentives. |
| NHLBI FY2027 budget justification | Congressional finance; FY2026 enacted distinguished from FY2027 request. Grants/cooperative agreements/contracts/intramural research. Exact historical award payments unclosed. | United States NIH; Bethesda. | Tier 3; fiscal self-report | B provisional. Actual 23-page original, selected enacted/request tables; no trial independence clearance. |
| NHLBI gift fund | Basic Congressional operating finance; separate permitted gifts/bequests from individuals/companies. Named actual gifts and trial allocation unclosed. | United States; 31 Center Drive, Bethesda. | Tier 3; own financial authority | B provisional. Authority differs from receipt or trial payment. |
| NCCIH appropriations history | Congressional appropriations reported through FY2024. FY2026 enacted total and exact safety-page allocation not established here. | United States NIH/HHS; Bethesda. | Tier 3; own fiscal history | B provisional. Actual dated series; not a current operating-plan amount. |
| NCCIH gift fund | Authorized voluntary donations/bequests; gift account separate from Congressional appropriation. Named receipts/page funding unclosed. | United States NIH/HHS; Bethesda. | Tier 3; own financial authority | B provisional. Permission is not a specific corporate payment. |
| NLM FY2027 budget justification | FY2026 enacted versus FY2027 request; public institute. Gift authority. Exact hosted-source allocation unclosed. | United States NIH; Bethesda. | Tier 3; fiscal self-report | B provisional. Actual budget tables; hosting does not clear maker, society or trial interests. |
| England PCA furosemide row | Agency finance. Programme/author allocation unclosed. | England community dispensing. | Tier 2; public statistics | B provisional. Actual Table 7 row 119; items, not patients or benefit. |
| PCA methodology 2026 | Shared NHSBSA finance below; exact allocation unclosed. | England community data. | Tier 2; public definitions | B provisional. June 2026. No worldwide-popularity inference. |
| NHSBSA accounts, 2025/26 | DHSC Parliamentary funding plus operating service/contract income; student-support receipts separately treated. Exact PCA allocation not identified. | United Kingdom; Newcastle upon Tyne. | Tier 3; own financial report | B provisional. Statutory accounts; selected funding notes read. Institutional route only. |
| NHS content policy | DHSC-funded website; advertising/corporate sponsorship excluded by policy; contributor declarations required. | United Kingdom. | Tier 3; own policy | C provisional. October 2022; review overdue. Contributor register unclosed. |
| SPS service commissioning | NHS England commissioning with nine host trusts/subcontractors. Published arrangements run to 31 March 2026; renewal and individual provider money unclosed. | United Kingdom; distributed providers, no single HQ verified. | Tier 3; own service statement | B provisional. Contract disclosure; dated coverage does not clear each author/page. |
| NHS England accounts, 2025/26 | DHSC grant-in-aid principally; additional service, research and consolidated charge/other income. Parent and consolidated routes differ; SPS allocation unidentified. | United Kingdom; Leeds contact address. | Tier 3; own financial report | B provisional. Selected notes read; commissioner finances do not replace host-trust ledgers. |
| eMC publisher original | Datapharm Ltd owns eMC; pharmaceutical companies pay subscriptions to publish approved manufacturer/regulator material. Exact product fee and complete investors/revenues unclosed. | United Kingdom; Cassini Court, Randalls Way, Leatherhead, Surrey. | Tier 4; commercial publishing source | D. Own full publishing/finance/contact body read; hosting does not clear trial interests. |
| MHRA Yellow Card | Public/industry-fee route below; exact service funding unclosed. | United Kingdom regulator. | Tier 3; reporting context | B provisional. Suspected events, no causation/rate proof. |
| MHRA accounts, 2025/26 | DHSC grant-in-aid plus statutory industry fees, customer/service income, research grants and biological-standard sales. | United Kingdom; London/Canary Wharf and South Mimms sites. | Tier 3; own financial report | B provisional. Selected current income notes read; exact safety-alert allocation unclosed. |
| NIH gift-administration policy | Conditional/unconditional gift authority with conflict checks; supplementary routes include authorised foundation transfers. Authority does not establish a named NLM donation. | United States; NIH-wide policy. | Tier 3; own financial policy | B provisional. Actual policy read; donor receipts and exact medicine-page allocations unclosed. |
Frequently asked questions
Is furosemide a cure for heart failure? No. It is one part of a broader plan determined by the type and severity of heart failure and other conditions. Care framework.
How much fluid? Ask your prescriber. Fluid advice.
Can tablets and Frusol be substituted by volume? Ask the pharmacist to verify strength, device and administration. Preparation.
Does the Lasix notice mean all furosemide was withdrawn? No. The determination concerns discontinued US Lasix tablets and distinguishes discontinuation from withdrawal for safety/effectiveness. It does not report local generic stock. Specific determination.
Sources and funding notes
Clinical and regulatory descriptions are context, not independently cleared comparative efficacy. Unidentified page allocations, supplier details, complete individual interests and beneficial fund investors remain unclosed.
Dated corporate reports do not establish historical investigator payments. Gift permission does not identify an actual receipt. Current product availability must be checked locally.
Selected original methods and published declarations were read; the reviewed evidence does not establish a personal dose, treatment conversion, fluid plan or infant-safety rule.
- NHS furosemide β Current clinical safety
- Ipca SmPC β Restrictions
- Ipca leaflet β Patient instructions
- Frusol leaflet β Liquid safety
- Hikma label β Restrictions
- SPS furosemide monitoring β Monitoring framework
- AHFS furosemide β Patient safety and mechanism
- NHS heart failure β Broader heart-failure care
- NHS anaphylaxis β Emergency recognition
- NCCIH supplement safety β Herbal safety limits
- Hopp official biography β Credited reviewer provenance
- Shurtleff official biography β Other credited reviewer
- TRANSFORM-HF original, 2023 β Methods and declared money
- FoR BP original, 2021 β Postpartum study limits
- Merck & Co/MSD 2025 results β Selected disclosed-counterparty route
- Merck & Co/MSD investor resources β Identity boundary
- Bayer annual report 2025 β Selected disclosed-counterparty route
- Ipca annual report 2025/26 β Tablet seller ownership/revenue
- Hikma financial statements 2025 β US seller business route
- Hikma governance report 2025 β Shareholding route
- Hikma own contact β Headquarters distinction
- Rosemont December 2025 statement β Liquid seller business route
- Rosemont filed control β Immediate control band
- Rosemont filing history β Audit-access gap
- Inflexion continuation fund announcement β Declared capital backers
- Inflexion portfolio, October 2025 β Dated investment corroboration
- Inflexion own locations β Manager jurisdiction
- Rubicon own venture record β Lasix holder group link
- Rubicon annual report 2024/25 β Dated group revenue/control
- ASHP treasurer report, 2025 β Content-owner revenue
- ASHP corporate/advertising routes β Commercial support channel
- ASHP historical corporate support β Historical named support
- FDA Lasix determination, August 2026 β Discontinuation distinction
- FDA FY2026 operating plan β Regulator revenue route
- NHLBI FY2027 budget justification β Public trial backer
- NHLBI gift fund β Separate possible funding channel
- NCCIH appropriations history β Public supplement-source finance
- NCCIH gift fund β Possible gift channel
- NLM FY2027 budget justification β Public hosting finance
- England PCA furosemide row β Prescribing count
- PCA methodology 2026 β Counting boundaries
- NHSBSA accounts, 2025/26 β Institutional finance
- NHS content policy β Website funding policy
- SPS service commissioning β Programme financial route
- NHS England accounts, 2025/26 β Commissioner finance
- eMC publisher original β Label publisher revenue
- MHRA Yellow Card β Suspected-event reporting
- MHRA accounts, 2025/26 β Safety regulator finance
- NIH gift-administration policy β Gift authority, not receipt
Educational research reviewed 5 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question β or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.